Iwu, Chinwe JulianaJordan, PortiaJaja, Ishmael FestusIwu, Chidozie DeclanWiysonge, Charles Shey2021-07-152021-07-152020-07-20Iwu, C.J., Jordan, P., Jaja, I.F., Iwu, C.D. Treatment of COVID-19: implications for antimicrobial resistance in Africa. Pan Africa Medical Journal. 2020;35(2):119 DOI: 10.11604/pamj.supp.2020.35.23713.1937-8688 (online)10.11604/pamj.supp.2020.35.23713http://hdl.handle.net/2263/80864There is currently no approved pharmaceutical product for the treatment of COVID-19. However, antibiotics are currently being used for the management of COVID-19 patients in many settings either treat to coinfections or for the treatment of COVID-19 itself. In this commentary, we highlight that the increased rates of antimicrobial prescribing for COVID-19 patients could further worsen the burden of antimicrobial resistance (AMR). We also highlight that though AMR is a global threat, Africa tends to suffer most from the consequences. We, therefore, call on African countries not to lose sight of the possible implications of the treatment of COVID-19 on AMR and a need to redouble efforts towards the fight against AMR while dealing with the pandemic.en© Chinwe Juliana Iwu et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License.AfricaCOVID-19 pandemicCoronavirus disease 2019 (COVID-19)Antimicrobial resistance (AMR)TreatmentArticle